Loading...
NPI 1427706852 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Advance Lab Company is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 1 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Advance Lab Company |
| Address | 2359 W Walnut St |
| City | Chicago |
| State | IL |
| ZIP | 60612 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 15, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $14.5M |
| Medicaid | $0 |
ADVANCE LAB COMPANY's reported Medicare billing is entirely concentrated in a single service line: K1034, which is described as provision of a nonprescription self-administered and self-collected FDA-approved or authorized COVID-19 test. The code mix indicates the operation is focused on distribution or provision of over-the-counter-style COVID-19 tests rather than a broad panel of clinical laboratory services, based on the single-code revenue profile.
Medicare revenue totaled $14.5M and the precomputed top-3 Medicare codes account for 100.0% of that total, signaling extreme revenue concentration in very few billable items. This degree of concentration implies the provider’s financial performance is tightly tied to reimbursement and utilization dynamics for that narrow set of codes.
The underlying activity driving the Medicare spend is high-volume, low-unit-payment testing: K1034 shows 1.3M claims at an $11 avg paid/claim producing $14.5M in revenue. That combination (very large claim count with a modest average paid/claim) is consistent with a high-throughput distribution or mass-test provisioning model rather than high-margin clinical assays.
For K1034 the provider ranks #29 of 30143 providers nationally and is labeled an "extreme outlier, far above typical national volume for this code," placing ADVANCE LAB COMPANY in the 100th percentile for national volume on this specific CPT/HCPCS. This national standing signals the organization is a major volume leader for this particular COVID-19 test code relative to peers across the country.
In-state Medicaid activity is effectively nil: Medicaid revenue is reported as $0 while Medicare revenue is $14.5M, meaning the provider operates as an effectively single-payer (Medicare) biller in the datasets provided. There is no Medicaid CPT/HCPCS data on file to evaluate state-level competitive standing or service mix for that payer.
The provider’s NPI was enumerated on 2022-03-15 (~4 years ago), and achieving $14.5M in Medicare revenue within that timeframe suggests rapid scaling in its chosen service area. Rapid volume build in a short tenure is consistent with a focused, transaction-driven distribution model rather than gradual expansion of diversified clinical services.
Because one code (K1034) drives all Medicare revenue, the provider’s financials are highly sensitive to coding, coverage, or payment policy changes affecting that code. Any Medicare payment adjustments or changes to eligibility for K1034 would have outsized impact on revenue and utilization for this entity.
Taken together, the code description, claim volume (1.3M claims), modest average paid/claim ($11), and national outlier rank suggest ADVANCE LAB COMPANY functions as a specialized, high-throughput provider of nonprescription COVID-19 tests. Analysts should treat this profile as narrowly focused operationally and consider that competitive comparisons should be made against other high-volume K1034 billers rather than broad-spectrum clinical laboratories.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,321,230 | $10 | $14.5M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 12 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 40 | $0 | $0 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 40 | $0 | $0 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 3,730 | $0 | $0 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 20 | $0 | $0 |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 40 | $0 | $0 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 40 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 41 | 50 | 710 | $70 | $1.2M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 179 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 348 | 400 | 550 | $20 | $90.8K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 21 | 20 | 1,750 | $10 | $66.6K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 681 | 910 | 110 | $30 | $14.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 8 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Advance Lab Company, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.